

Outline of Initial Listing Issue

ASKA Pharmaceutical Holdings Co.,Ltd. (hereinafter "the Company"), which is scheduled for listing on Apr. 1, 2021, is the wholly-owning parent company to be established by listed company ASKA Pharmaceutical Co., Ltd. (Code: 4514, Market Division: 1st Section) via stock transfer. Because the Company has not been established at the time of this document's release, this document contains estimations and predictions regarding the conditions as of Apr. 1, 2021, the day of the company's establishment.

Company Name	ASKA Pharmaceutical Holdings Co.,Ltd.	
Scheduled Listing Date	Apr. 1, 2021	
Market Section	1st Section	
Current Listed Market	N/A	
Name and Title of Representative	YAMAGUCHI Takashi, President, Representative Director	
Address of Main Office	2-5-1 Shibaura, Minato-ku, Tokyo, 108-8532	
(Closest Point of Contact)	Tel. Unfixed (Scheduled to be established on Apr. 1, 2021)	
(Contact Details of Wholly-owned Subsidiary)	(Same as above)	
Home Page	ASKA Pharmaceutical Co., Ltd.	Tel. +81- 3-5484-8361
Date of Incorporation	https://www.aska-pharma-hd.co.jp/	
Description of Business	(Scheduled to be established on Apr. 1, 2021)	
Category of Industry/ Code	Apr. 1, 2021	
Authorized Total No. of Shares to be Issued	Business management of subsidiaries, etc. that engage in manufacturing, sale, import/export, clinical examinations and testing operations of pharmaceuticals, quasi-drugs, foods, veterinary drugs, feeds and feed additives and medical devices, etc. and related operations	
No. of Issued Shares (incl. treasury shares) at the time of Listing	Pharmaceutical • 4886 (ISIN JP3119660003)	
Capital	90,000,000 shares	
No. of Shares per Share Unit	30,563,199 shares	
Business Year	Note: If the total number of issued shares of ASKA Pharmaceutical Co., Ltd. changes before the stock transfer comes into force, the total number of issued shares of ASKA Pharmaceutical Holdings Co.,Ltd. as of Apr. 1, 2021 may change.	
General Shareholders Meeting	JPY 1,197,900 thousand	
Record Date	100 shares	
Record Date of Surplus Dividend	From Apr. 1 to Mar. 31 of the following year	
Transfer Agent	In June	
Auditor	Mar. 31	
	Sep. 30 and Mar. 31	
	Mitsubishi UFJ Trust and Banking Corporation	
	Seiyo Audit Corporation	

(Appendix) ASKA Pharmaceutical Co., Ltd. will be delisted on Mar. 30, 2021.

© 2021 Tokyo Stock Exchange, Inc. All rights reserved.

DISCLAIMER: This translation may be used for reference purposes only. This English version is not an official translation of the original Japanese document. In cases where any differences occur between the English version and the original Japanese version, the Japanese version shall prevail. This translation is subject to change without notice. Tokyo Stock Exchange, Inc. and/or Japan Exchange Regulation shall individually or jointly accept no responsibility or liability for damage or loss caused by any error, inaccuracy, misunderstanding, or changes with regard to this translation.

(Reference Translation)

- (Note 1) The company is an initial listing under technical listings prescribed in Rule 208 of the Securities Listing Regulations. In listing examinations of technical listings, Japan Exchange Regulation focuses on whether or not the newly-established company meets certain formal listing criteria at the time of listing. Such listing examinations are different from regular initial listing examinations conducted in detail from perspectives such as corporate continuity and profitability, and soundness of corporate management.
- (Note 2) Documents such as the "Securities Report for Initial Listing Application (Part I)" are available on the JPX website at (<https://www.jpx.co.jp/>) (only in Japanese).

© 2021 Tokyo Stock Exchange, Inc. All rights reserved.

DISCLAIMER: This translation may be used for reference purposes only. This English version is not an official translation of the original Japanese document. In cases where any differences occur between the English version and the original Japanese version, the Japanese version shall prevail. This translation is subject to change without notice. Tokyo Stock Exchange, Inc. and/or Japan Exchange Regulation shall individually or jointly accept no responsibility or liability for damage or loss caused by any error, inaccuracy, misunderstanding, or changes with regard to this translation.